Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022Business Wire • 09/15/22
EQ Stock Alert: Halper Sadeh LLP is Investigating Whether the Merger of Equillium, Inc. is Fair to ShareholdersBusiness Wire • 09/06/22
Equillium Reports Second Quarter 2022 Financial Results and Provides Clinical Development UpdatesBusiness Wire • 08/15/22
Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development SummitBusiness Wire • 07/28/22
Equillium Reports First Quarter 2022 Financial Results and Provides Corporate and Clinical Development UpdatesBusiness Wire • 05/12/22
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology AssociationBusiness Wire • 05/12/22
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of ImmunologistsBusiness Wire • 05/09/22
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTRBusiness Wire • 04/25/22
Equillium Announces Oral Presentation at the Italian Society of Experimental HematologyBusiness Wire • 04/04/22
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)Zacks Investment Research • 03/29/22
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development UpdatesBusiness Wire • 03/23/22
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow TransplantationBusiness Wire • 03/23/22
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host DiseaseBusiness Wire • 03/04/22
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug CandidatesBusiness Wire • 02/16/22
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTRBusiness Wire • 01/10/22